This company listing is no longer active
Valens (VLNS) Stock Overview
The Valens Company Inc., through its subsidiaries, develops, manufactures, and sells cannabinoid-based products in Canada, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
VLNS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
The Valens Company Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.01 |
| 52 Week High | CA$3.79 |
| 52 Week Low | CA$0.76 |
| Beta | 1.79 |
| 1 Month Change | 12.22% |
| 3 Month Change | 9.78% |
| 1 Year Change | -59.44% |
| 3 Year Change | -91.02% |
| 5 Year Change | -86.15% |
| Change since IPO | -32.67% |
Recent News & Updates
Recent updates
These Analysts Just Made A Huge Downgrade To Their The Valens Company Inc. (TSE:VLNS) EPS Forecasts
Mar 05
Some Analysts Just Cut Their The Valens Company Inc. (TSE:VLNS) Estimates
Feb 09Is Valens (TSE:VLNS) Using Debt Sensibly?
Oct 19When Will The Valens Company Inc. (TSE:VLNS) Breakeven?
Mar 24The Valens Company Inc. (TSE:VLNS) Analysts Just Cut Their EPS Forecasts
Jan 22Is Valens (TSE:VLNS) Using Too Much Debt?
Dec 08Shareholder Returns
| VLNS | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -1.9% | -2.7% | 2.4% |
| 1Y | -59.4% | 48.8% | 41.4% |
Return vs Industry: VLNS matched the Canadian Pharmaceuticals industry which returned -59.9% over the past year.
Return vs Market: VLNS underperformed the Canadian Market which returned -3% over the past year.
Price Volatility
| VLNS volatility | |
|---|---|
| VLNS Average Weekly Movement | 13.4% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 10.9% |
| 10% most volatile stocks in CA Market | 18.9% |
| 10% least volatile stocks in CA Market | 3.9% |
Stable Share Price: VLNS's share price has been volatile over the past 3 months.
Volatility Over Time: VLNS's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 445 | n/a | www.thevalenscompany.com |
The Valens Company Inc., through its subsidiaries, develops, manufactures, and sells cannabinoid-based products in Canada, the United States, and internationally. The company provides packaged dried flower/pre-rolls under the Verse, Versus, Contraband, and Citizen Stash brands; vapourizers and hydrocarbon extracts under the Verse and Versus brands; edible cannabis products under the Verse, Vacay, and LYF brands; and topical cannabis under the Nuance brand. It also offers analytical testing services to third party licensed producers in the cannabis space.
The Valens Company Inc. Fundamentals Summary
| VLNS fundamental statistics | |
|---|---|
| Market cap | CA$81.67m |
| Earnings (TTM) | -CA$235.52m |
| Revenue (TTM) | CA$85.89m |
Is VLNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VLNS income statement (TTM) | |
|---|---|
| Revenue | CA$85.89m |
| Cost of Revenue | CA$88.93m |
| Gross Profit | -CA$3.03m |
| Other Expenses | CA$232.49m |
| Earnings | -CA$235.52m |
Last Reported Earnings
Aug 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.91 |
| Gross Margin | -3.53% |
| Net Profit Margin | -274.21% |
| Debt/Equity Ratio | 75.7% |
How did VLNS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/19 11:47 |
| End of Day Share Price | 2023/01/18 00:00 |
| Earnings | 2022/08/31 |
| Annual Earnings | 2021/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The Valens Company Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Kideckel | ATB Cormark |
| Kimberly Thompson-Hedlin | Canaccord Genuity |
| John Chu | Desjardins Securities Inc. |